The PE Ratio as of July 2024 (TTM) for Verona Pharma plc (VRNA) is -28.41

According to Verona Pharma plc’s latest financial reports and current stock price. The company's current PE Ratio is -28.41. This represents a change of 3.05% compared to the average of -27.57 of the last 4 quarters.

Verona Pharma plc (VRNA) Historical PE Ratio (quarterly & annually)

How has VRNA PE Ratio performed in the past?

The mean historical PE Ratio of Verona Pharma plc over the last ten years is -707.78. The current -28.41 PE Ratio has changed 301.39% with respect to the historical average. Over the past ten years (40 quarters), VRNA's PE Ratio was at its highest in in the June 2018 quarter at 424.95. The PE Ratio was at its lowest in in the December 2016 quarter at -261.49.

Verona Pharma plc (VRNA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Verona Pharma plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Verona Pharma plc (VRNA) Average PE Ratio

How has VRNA PE Ratio performed in the past?

The current PE Ratio of Verona Pharma plc (VRNA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Verona Pharma plc (VRNA) PE Ratio vs. Peers

How is VRNA’s PE Ratio compared to its peers?

Verona Pharma plc’s PE Ratio is less than Ventyx Biosciences, Inc. (-0.95), less than IDEAYA Biosciences, Inc. (-24.70), less than Protagonist Therapeutics, Inc. (15.12), less than Syndax Pharmaceuticals, Inc. (-8.67), less than Day One Biopharmaceuticals, Inc. (-6.65), less than X4 Pharmaceuticals, Inc. (-1.34), less than Inozyme Pharma, Inc. (-4.67), less than Acumen Pharmaceuticals, Inc. (-3.72), greater than Mereo BioPharma Group plc (-82.75), less than Terns Pharmaceuticals, Inc. (-7.36), less than Amylyx Pharmaceuticals, Inc. (-1.88), greater than MoonLake Immunotherapeutics (-68.94), less than Mirati Therapeutics, Inc. (-5.32), less than Apellis Pharmaceuticals, Inc. (-11.71), less than Akero Therapeutics, Inc. (-9.30), less than Madrigal Pharmaceuticals, Inc. (-12.81), greater than Viking Therapeutics, Inc. (-75.29),

Build a custom stock screener for Verona Pharma plc (VRNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verona Pharma plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Verona Pharma plc (VRNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Verona Pharma plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.